2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline‐concordant lung cancer staging
Farjah F, Barta J, Wood D, Rivera M, Osarogiagbon R, Smith R, Mullett T, Rosenthal L, Henderson L, Detterbeck F, Silvestri G. The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline‐concordant lung cancer staging. Cancer 2024 PMID: 39347610, DOI: 10.1002/cncr.34627.Peer-Reviewed Original ResearchLung cancer stagingCancer stageGuideline recommendationsPerformance feedback mechanismsLung cancerPatient self-advocacyImproving lung cancer stagingCurrent health policyPractice guideline recommendationsCancer treatmentProfessional societiesStage lung cancerLung cancer survivalStage-appropriate therapyLevel of evidenceComparative-effectiveness studiesHealth policyHealth systemCancer survivalLow-to-moderateAccurate stagingRecommended 4Practice guidelinesSelf-advocacyMultidisciplinary expertsThe Proposed Ninth Edition TNM Classification of Lung Cancer
Detterbeck F, Woodard G, Bader A, Dacic S, Grant M, Park H, Tanoue L. The Proposed Ninth Edition TNM Classification of Lung Cancer. CHEST Journal 2024, 166: 882-895. PMID: 38885896, DOI: 10.1016/j.chest.2024.05.026.Peer-Reviewed Original ResearchThe International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer
Rami-Porta R, Nishimura K, Giroux D, Detterbeck F, Cardillo G, Edwards J, Fong K, Giuliani M, Huang J, Kernstine K, Marom E, Nicholson A, Van Schil P, Travis W, Tsao M, Watanabe S, Rusch V, Asamura H, Boards A. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2024, 19: 1007-1027. PMID: 38447919, DOI: 10.1016/j.jtho.2024.02.011.Peer-Reviewed Original ResearchClassification of lung cancerLung cancerTNM classificationStage groupSignificance of survival differencesInternational Association for the Study of Lung CancerLung Cancer Staging ProjectTNM stage groupingTNM classification of lung cancerStudy of Lung CancerEdition TNMStage NSCLCPathological stageClinical stageSurvival differencesAnatomic extentTNMSurvival analysisTreatment approachesCancerStatistical significanceMultivariate regressionPatientsLungThe International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, Marino M, Marom E, Putora P, Singh N, Suárez F, Rami-Porta R, Detterbeck F, Eberhardt W, Asamura H, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee M. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2024, 19: 786-802. PMID: 38320664, DOI: 10.1016/j.jtho.2024.01.019.Peer-Reviewed Original ResearchM1c patientsClassification of non-small cell lung cancerNon-small cell lung cancerLung Cancer Staging ProjectMultivariable-adjusted Cox proportional hazards regressionKaplan-Meier methodCell lung cancerCox proportional hazards regressionOrgan systemsProportional hazards regressionM1b categoryM1c categoryMetastatic categoriesMultiple metastasesMetastatic lesionsOverall survivalTNM classificationCurrent tumorLung cancerM categoryHazards regressionM descriptorsDecreased prognosisPotential confoundersMetastasis
2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changesThe International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Van Schil P, Asamura H, Nishimura K, Rami-Porta R, Kim Y, Bertoglio P, Cangir A, Donington J, Fang W, Giroux D, Lievens Y, Liu H, Lyons G, Sakai S, Travis W, Ugalde P, Yang C, Yotsukura M, Detterbeck F, Committee A. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 749-765. PMID: 38070600, PMCID: PMC11081813, DOI: 10.1016/j.jtho.2023.12.006.Peer-Reviewed Original ResearchLung cancerT descriptorChest wallTNM classificationInternational Association for the Study of Lung CancerInternational Association for the Study of Lung Cancer databaseMultivariate Cox regression analysisLung Cancer Staging ProjectInclusion criteriaPathologically staged tumorsCox regression analysisTNM classification of lung cancerClassification of lung cancerDate of diagnosisStudy of Lung CancerLung cancer databaseNinth EditionPleura involvementT3 descriptorsT4 tumorsWorse survivalCancer DatabaseComprehensive survival analysisPathological typeUnivariate analysis
2021
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, David E, Detterbeck F, Früh M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB. Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline. Journal Of Clinical Oncology 2021, 40: 1356-1384. PMID: 34936470, DOI: 10.1200/jco.21.02528.Peer-Reviewed Original ResearchConceptsStage III NSCLCManagement of patientsCell lung cancerEvidence-based recommendationsLung cancerStage IIIEvidence-based guideline recommendationsUnresectable stage III NSCLCLiterature searchRecurrence-free survivalWorkup of patientsOutcomes of interestQuality of lifeAdvocacy expertsCommunity oncologyASCO guidelinesAdjuvant approachGuideline recommendationsSurgical managementMedical oncologyThoracic surgeryPulmonary oncologyExpert panel membersSystematic reviewPatientsPretreatment Invasive Nodal Staging in Lung Cancer Knowledge, Attitudes, and Beliefs Among Academic and Community Physicians
Henderson LM, Farjah F, Detterbeck F, Smith RA, Silvestri GA, Rivera MP. Pretreatment Invasive Nodal Staging in Lung Cancer Knowledge, Attitudes, and Beliefs Among Academic and Community Physicians. CHEST Journal 2021, 161: 826-832. PMID: 34801593, PMCID: PMC9069181, DOI: 10.1016/j.chest.2021.11.010.Peer-Reviewed Original ResearchConceptsInvasive nodalGuideline adherenceGuideline recommendationsNodal stagingTreatment decisionsThoracic surgeonsNon-small cell lung cancerCell lung cancerBetter patient outcomesAppropriate treatment decisionsLung cancer knowledgeLack of evidenceChest PhysiciansTreatment delayCancer knowledgeLung cancerPatient anxietyPatient outcomesCommunity physiciansAmerican CollegeMost physiciansInsufficient evidenceRoutine practiceWeb-based surveyMultilevel interventionsExecutive Summary Screening for Lung Cancer: Chest Guideline and Expert Panel Report
Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, Wiener RS, Detterbeck FC. Executive Summary Screening for Lung Cancer: Chest Guideline and Expert Panel Report. CHEST Journal 2021, 160: 1959-1980. PMID: 34270965, PMCID: PMC8727851, DOI: 10.1016/j.chest.2021.07.003.Peer-Reviewed Original ResearchConceptsNational Lung Screening TrialLow-dose chest CTLung cancerCT screeningChest CTClinical questionsLow-dose CT screeningEvidence baseLow-dose chest CT screeningAdditional clinical questionsScreen-detected findingsScreening-eligible individualsGrading of RecommendationsChest CT screeningStandard of careImportant clinical questionsSystematic literature reviewExpert Panel ReportLow-dose CTCHEST GuidelineCessation interventionsCochrane LibraryGuideline publicationLiterature reviewConsensus statementScreening for Lung Cancer CHEST Guideline and Expert Panel Report
Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, Wiener RS, Detterbeck FC. Screening for Lung Cancer CHEST Guideline and Expert Panel Report. CHEST Journal 2021, 160: e427-e494. PMID: 34270968, PMCID: PMC8727886, DOI: 10.1016/j.chest.2021.06.063.Peer-Reviewed Original ResearchConceptsNational Lung Screening TrialLow-dose chest CTLung cancerCT screeningChest CTClinical questionsLow-dose CT screeningEvidence baseLow-dose chest CT screeningAdditional clinical questionsScreen-detected findingsScreening-eligible individualsGrading of RecommendationsChest CT screeningStandard of careImportant clinical questionsSystematic literature reviewExpert Panel ReportLow-dose CTCHEST GuidelineCessation interventionsCochrane LibraryGuideline publicationLiterature reviewConsensus statementRates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion size
2020
Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report. CHEST Journal 2020, 158: 406-415. PMID: 32335067, PMCID: PMC7177089, DOI: 10.1016/j.chest.2020.04.020.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCHEST Expert Panel ReportCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicExpert Panel ReportPotential exposureManagement of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report. Journal Of The American College Of Radiology 2020, 17: 845-854. PMID: 32485147, PMCID: PMC7177099, DOI: 10.1016/j.jacr.2020.04.024.Peer-Reviewed Original ResearchConceptsLung cancer screeningCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerStage INodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsClinical stage ICHEST Expert Panel ReportCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicExpert Panel ReportPotential exposureGuideline recommendationsManagement of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiology Imaging Cancer 2020, 2: e204013. PMID: 33778716, PMCID: PMC7233408, DOI: 10.1148/rycan.2020204013.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicPotential exposureGuideline recommendationsSurveillance imagingRadiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline
Simone CB, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology 2020, 10: 158-173. PMID: 32222430, PMCID: PMC10915746, DOI: 10.1016/j.prro.2020.02.009.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerStereotactic body radiation therapyProphylactic cranial irradiationES-SCLCCell lung cancerThoracic RTLS-SCLCLung cancerRadiation therapyExtensive-stage (ES) SCLCNode-negative small cell lung cancerStage IASTRO Clinical Practice GuidelineInvolved field RTRadiation oncologist consultationStage I patientsNode-negative diseaseClinical practice guidelinesRadiation Oncology guidelinesBody radiation therapyCourse of treatmentGood clinical practiceAmerican SocietyAdvanced treatment modalitiesAdjuvant RTApproach to the Subsolid Nodule
Mase VJ, Detterbeck FC. Approach to the Subsolid Nodule. Clinics In Chest Medicine 2020, 41: 99-113. PMID: 32008632, DOI: 10.1016/j.ccm.2019.11.004.Peer-Reviewed Original Research
2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal Of Clinical Oncology 2019, 38: 753-766. PMID: 31829901, DOI: 10.1200/jco.19.02748.Peer-Reviewed Original ResearchConceptsCurative-intent therapyLung cancerStage IFluorodeoxyglucose positron emission tomography/Evidence-based guideline recommendationsNew primary lung cancerRetrospective comparative observational studySurveillance strategiesSmall cell lung cancerBrain magnetic resonance imagingLiterature searchPositron emission tomography/Lung cancer surveillanceCurative-intent treatmentPrimary lung cancerRecurrence-free survivalCell lung cancerDetection of recurrenceComparative observational studyEmission tomography/Optimal imaging modalityEvidence-based recommendationsOutcomes of interestQuality of lifeMagnetic resonance imaging
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatientsIdentifying Drivers of Multiple Readmissions After Pulmonary Lobectomy
Jean RA, Chiu AS, Hoag JR, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Identifying Drivers of Multiple Readmissions After Pulmonary Lobectomy. The Annals Of Thoracic Surgery 2018, 107: 947-953. PMID: 30336117, DOI: 10.1016/j.athoracsur.2018.08.070.Peer-Reviewed Original ResearchConceptsPulmonary lobectomyMultiple readmissionsSecond readmissionFirst readmissionIndex hospitalizationPostoperative infectionLung cancerPrimary diagnosisHeart diseaseClinical Classification Software codesNationwide Readmissions DatabaseTime of readmissionPostoperative arrhythmiasPostoperative complicationsPostoperative sepsisPerioperative periodPostoperative periodClinical factorsReadmissionLobectomyPatientsStudy periodImportant markerDiagnosisHealthcare qualityDelayed discharge does not decrease the cost of readmission after pulmonary lobectomy
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD. Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy. Surgery 2018, 164: 1294-1299. PMID: 30064733, DOI: 10.1016/j.surg.2018.05.049.Peer-Reviewed Original ResearchConceptsRisk-adjusted readmission ratesReadmission ratesLate dischargeDischarge groupPulmonary lobectomyCostly readmissionsLung cancerHospital costsOverall health care utilizationExcess health care costsRoutine dischargeCosts of readmissionIndex hospital costsLate discharge groupRoutine discharge groupPatients 65 yearsNationwide Readmissions DatabaseHospital day 1Hospital day 4Health care utilizationCases of lobectomyHealth care costsIndex hospitalHospital durationCare utilization